What is Resistell?
Resistell is at the forefront of developing innovative diagnostic solutions, particularly for antibiotic susceptibility testing. Their proprietary diagnostic device, Resistell Phenotech, is designed to address critical challenges in rapid diagnostics, aiming to accelerate the identification of effective antibiotic treatments. This technology holds the potential to revolutionize how healthcare providers combat antibiotic resistance, a pressing global health concern.
How much funding has Resistell raised?
Resistell has raised a total of $9.1M across 1 funding round:
Series B
$9.1M
Series B (2022): $9.1M with participation from Zürcher Kantonalbank, Occident, EIC Fund, and TRUMPF Venture
Key Investors in Resistell
Zürcher Kantonalbank
Zürcher Kantonalbank is a leading Swiss universal bank offering a comprehensive range of financial products and services, including business financing and capital market transactions, indicating a strong interest in supporting established growth-stage companies.
Occident
OCCIDENT is an owner-managed venture capital investor focused on innovative deep tech start-ups in life sciences and digital technologies, with a preference for seed rounds or later, suggesting a strategic alignment with Resistell's advanced diagnostic technology.
EIC Fund
Undisclosed investor participating in the funding round.
What's next for Resistell?
With this substantial enterprise-level funding, Resistell is poised for significant expansion and further development of its groundbreaking diagnostic platform. The strategic investment will likely fuel advancements in R&D, scale manufacturing capabilities, and broaden market penetration. The company's focus on accelerating antibiotic susceptibility testing positions it as a key player in the fight against antimicrobial resistance, suggesting a trajectory towards becoming a leader in advanced medical diagnostics.
See full Resistell company page
